Trials / Completed
CompletedNCT04096950
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
A Study to Investigate the Safety, Tolerability , Pharmacokinetics of Single Ascending Dose of MT-3921 in Subjects With Acute Spinal Cord Injury
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Tanabe Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
Detailed description
This is a Phase 1, open-label, single ascending dose study of MT-3921 in subjects with spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MT-3921 Low dose | MT-3921 Low dose, intravenous, single dosing |
Timeline
- Start date
- 2020-04-19
- Primary completion
- 2021-01-06
- Completion
- 2021-01-06
- First posted
- 2019-09-20
- Last updated
- 2023-05-15
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04096950. Inclusion in this directory is not an endorsement.